Saif Alenizi
Nephrology · Boston, MANPI 1255680997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,232 of the $18,745 with a category attached, or 81.3%. 4 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 56.6% of the total. Reporting peaked in 2024 at $13,398 and has fallen 98.9% since, to $141 in 2025.
Across 26 payments — averaging $720.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$11K
- Calliditas Therapeutics US Inc.$7K
- Nxstage Medical, Inc.$700
- Travere Therapeutics, Inc.$94
Across 6 payments — averaging $27,222 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$94K
- Vertex$46K
- Genentech, Inc.$15K
- AstraZeneca$8K
What the payments were for
- Consulting fees$15,23281%
- Speaking & faculty fees$2,25012%
- Travel & lodging$9275%
- Food & beverage$2421%
- Education$941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $10,601 |
| Calliditas Therapeutics US Inc. | 3 | $7,350 |
| Nxstage Medical, Inc. | 1 | $700 |
| Travere Therapeutics, Inc. | 12 | $94 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$7,350
- NXSTAGE SYSTEM ONE$700
How this compares
$18,745 in reported general payments places this provider in the 85th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Envarsus XrTacrolimus | 14 | $22,086 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $17,882 |
| Everolimus | 12 | $14,048 |
| Atovaquone | 24 | $6,118 |
| Mycophenolic AcidMycophenolate Sodium | 13 | $2,762 |
| Mycophenolate Mofetil | 14 | $2,560 |
| Torsemide | 24 | $824 |
| Prednisone | 34 | $375 |
| Losartan Potassium | 33 | $333 |
| Amlodipine Besylate | 22 | $303 |
| Carvedilol | 21 | $294 |
| Calcitriol | 23 | $160 |
| Atorvastatin Calcium | 12 | $153 |
| Furosemide | 24 | $35 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boston
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Leslie FangBoston$388K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
- Andrew AllegrettiBoston$139K
- Ravi ThadhaniBoston$115K
- Meghan SiseBoston$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.